Diligence memo · auto-generated · as of July 2, 2026
Seraph Biosciences, Inc.
Seraph Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Seraph Biosciences, Inc. operates in Biotechnology, based in DETROIT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Seraph Biosciences, Inc. has raised $10M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2018-12-21.
Most recent recorded round closed around 2018-12-21.
Valuation (modeled)modeled
Provath models Seraph Biosciences, Inc. at approximately $254M (range $7.7M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 7.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 57% of Biotechnology peers (4293 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.